Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation
- PMID: 20304212
- DOI: 10.1016/j.transproceed.2010.02.011
Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation
Abstract
Background: Mammalian target of rapamycin (mTOR) inhibitors behave as potent immunosuppressants, which have the advantages, with respect to calcineurin inhibitors (CNI; cyclosporine or tacrolimus), of no nephrotoxicity but inhibition of cell proliferation. They are particularly suitable for patients with renal insufficiency or neoplasias.
Materials and methods: Twenty-eight liver transplant patients were immunosuppressed with everolimus or sirolimus as rescue therapy after CNI treatment: 8 hepatocellular carcinomas; 7 de novo malignancies; 6 renal insufficiencies; 3 chronic rejections; 3 acute rejection episodes; and 1 epilepsy.
Results: There were 0% tumor recurrences, 50% improvements in 33% no change, and 17% worsening of renal function among cases of renal insufficiency; 0% improvement in cases of chronic rejection, and 33% improvement in acute rejection episodes. There was a 7% incidence of acute rejection episodes, but no kidney failure, gastrointestinal intolerance, hydrocarbon intolerance, hypertension, or arterial or venous thrombosis. Diarrhea occurred in 7%; hypercholesterolemi in 46% hypertriglyceridemia in 50% thrombocytopenia in 14%, leukopenia in 14%, and anemia in 39%. The 12% intercurrent infection rate included oral thrush in 11%. Lower limb edema occurred in 21%; 1 case displayed facial edema and 1, alopecia.
Conclusions: mTOR inhibitors were safe immunosuppressive drugs whose side effects were controlled and easily managed. They have advantages with respect to CNI due to their slight effects on kidney function and lack of promotion of diabetes mellitus. Although their long-term effectiveness for control of neoplastic diseases is yet to be seen, they can be used safely in these patients with a low incidence of rejection. Their effectiveness to control steroid-resistant acute rejection episodes or renal insufficiency seems significant, but they are of doubtful benefit for chronic rejection.
Copyright (c) 2010. Published by Elsevier Inc.
Similar articles
-
Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.Transplant Proc. 2009 Jul-Aug;41(6):2181-3. doi: 10.1016/j.transproceed.2009.06.083. Transplant Proc. 2009. PMID: 19715866
-
Everolimus in clinical practice in long-term liver transplantation: an observational study.Transplant Proc. 2011 Jul-Aug;43(6):2216-9. doi: 10.1016/j.transproceed.2011.06.015. Transplant Proc. 2011. PMID: 21839237
-
mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?J Nephrol. 2010 Mar-Apr;23(2):133-42. J Nephrol. 2010. PMID: 20155724 Review.
-
A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.Exp Clin Transplant. 2008 Jun;6(2):113-7. Exp Clin Transplant. 2008. PMID: 18816237
-
Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.Transplant Proc. 2008 Dec;40(10 Suppl):S17-20. doi: 10.1016/j.transproceed.2008.10.019. Transplant Proc. 2008. PMID: 19100899 Review.
Cited by
-
Immunosuppressants in cancer prevention and therapy.Oncoimmunology. 2013 Dec 1;2(12):e26961. doi: 10.4161/onci.26961. Epub 2013 Nov 6. Oncoimmunology. 2013. PMID: 24575379 Free PMC article. Review.
-
Exploring the mTOR Signalling Pathway and Its Inhibitory Scope in Cancer.Pharmaceuticals (Basel). 2023 Jul 14;16(7):1004. doi: 10.3390/ph16071004. Pharmaceuticals (Basel). 2023. PMID: 37513916 Free PMC article. Review.
-
Metabolic Disorders in Liver Transplant Recipients: The State of the Art.J Clin Med. 2024 Feb 9;13(4):1014. doi: 10.3390/jcm13041014. J Clin Med. 2024. PMID: 38398327 Free PMC article. Review.
-
Lipids in liver transplant recipients.World J Gastroenterol. 2016 Mar 28;22(12):3315-24. doi: 10.3748/wjg.v22.i12.3315. World J Gastroenterol. 2016. PMID: 27022213 Free PMC article. Review.
-
mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation.Blood. 2016 Aug 4;128(5):615-24. doi: 10.1182/blood-2015-10-672964. Epub 2016 Jun 10. Blood. 2016. PMID: 27288518 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous